Androgenic Alopecia - Therapeutics Assessment Pipeline Review, H1 2014 adds “Androgenic Alopecia – Pipeline Review, H1 2014” to its store. The report provides an overview of the Androgenic Alopecia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Androgenic Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Androgenic Alopecia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Complete report available @ .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


  • The report provides a snapshot of the global therapeutic landscape of Androgenic Alopecia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Androgenic Alopecia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Androgenic Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Androgenic Alopecia Overview 6
Therapeutics Development 7
Pipeline Products for Androgenic Alopecia - Overview 7
Pipeline Products for Androgenic Alopecia - Comparative Analysis 8
Androgenic Alopecia - Therapeutics under Development by Companies 9
Androgenic Alopecia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Androgenic Alopecia - Products under Development by Companies 13
Androgenic Alopecia - Companies Involved in Therapeutics Development 14
Allergan, Inc. 14
Histogen, Inc. 15
R-Tech Ueno, Ltd. 16
Hygeia Therapeutics, Inc. 17
SWITCH Biotech LLC 18
Polichem S.A. 19
Kasiak Research Pvt. Ltd. 20
Androgenic Alopecia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
bimatoprost - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RK-023 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Refagro - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RCH-01 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Hair Stimulating Complex (HSC) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
finasteride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SM-04554 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HYG-440 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(HYG-102 + HYG-440) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule for Androgenic Alopecia - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Androgenic Alopecia - Recent Pipeline Updates 45
Androgenic Alopecia - Dormant Projects 48
Androgenic Alopecia - Product Development Milestones 49
Featured News & Press Releases 49
May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness 49
Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine 49
Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology 50
Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

Browse more reports on Therapeutics Market @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.